Burden-of-illness of Dutch community-dwelling older adults with sarcopenia: health related outcomes and costs

D.M. Mijnarends; J.M.G.A. Schols; R.J.G. Halfens; J.M.M. Meijers; Y.C. Luiking; S. Verlaan; S.M.A.A. Evers

doi:10.1016/j.eurger.2015.12.011

Burden-of-illness of Dutch community-dwelling older adults with sarcopenia: health related outcomes and costs

D.M. Mijnarends^*, J.M.G.A. Schols, R.J.G. Halfens, J.M.M. Meijers, Y.C. Luiking, S. Verlaan, S.M.A.A. Evers

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Objective: To explore the burden-of-illness of Dutch community-dwelling older adults with sarcopenia, in terms of disability in activities of daily living (ADL), quality of life (QoL) and costs from a societal perspective.

Methods: The Maastricht Sarcopenia Study (MaSS) was performed in adults >= 65 y, receiving (1) no care, (2) home care/assisted living facility, or (3) care in a residential living facility. Sarcopenia was defined according to the European Working Group on Sarcopenia algorithm. Disability in ADL was measured with the Groningen Activity Restriction Scale (GARS); QoL with the EQ-5D-5L. Subjects were questioned about their health care use and health-related costs (societal perspective). Data are presented for sarcopenic and (age and sex matched) non-sarcopenic subjects. Bootstrapping was performed to estimate 95%CI around the mean costs. Several subgroup (age, sex, living situation, comorbidities) and sensitivity analyses were performed.

Results: Sarcopenic subjects (n = 53) scored significantly worse on health-related outcomes compared with non-sarcopenic subjects (n = 174; GARS 29 +/- 11.3 vs. 22 +/- 7.3, P <0.001, QoL 0.78 +/- 0.2 vs. 0.86 +/- 0.2, P = 0.001). This difference was, except for the subscale ADL, no longer significant when compared with age and sex matched non-sarcopenic subjects (GARS 27 +/- 10.6, P = 0.097, QoL 0.81 +/- 0.2, P = 0.362). Mean health care costs of sarcopenic subjects ((sic)4325, 95% CI: (sic)3198-(sic)5471) were significantly higher than those of non-sarcopenics ((sic)1533, 95% CI: (sic)1153-(sic)1912), and higher, i.e. (sic)1557 per three months (though not significant) compared with age and sex matched non-sarcopenics ((sic)2768, 95% CI: (sic)1914-(sic)3743). Living situation (residential care) was a main driver of costs.

Conclusions: Community-dwelling sarcopenic older adults had a higher health and economic burden than non-sarcopenic older adults. This was importantly driven by the living situation -keeping older adults independent and out of care-dependent settings may contribute to a reduction of health care costs. (C) 2016 Elsevier Masson SAS and European Union Geriatric Medicine Society. All rights reserved.

Original language	English
Pages (from-to)	276-284
Number of pages	9
Journal	European Geriatric Medicine
Volume	7
Issue number	3
DOIs	https://doi.org/10.1016/j.eurger.2015.12.011
Publication status	Published - Jun 2016

Keywords

Muscle mass
Independently living
Assisted living
Costs
Disability
Quality of life
PHYSICAL-DISABILITY
MUSCLE MASS
HERTFORDSHIRE COHORT
INCIDENT DISABILITY
CARE COSTS
PEOPLE
LIFE
FRAILTY
PREDICTION
STRENGTH

Access to Document

10.1016/j.eurger.2015.12.011

Cite this

@article{2beb9d39608c4043aaf7eb9c4b745ba2,

title = "Burden-of-illness of Dutch community-dwelling older adults with sarcopenia: health related outcomes and costs",

abstract = "Objective: To explore the burden-of-illness of Dutch community-dwelling older adults with sarcopenia, in terms of disability in activities of daily living (ADL), quality of life (QoL) and costs from a societal perspective.Methods: The Maastricht Sarcopenia Study (MaSS) was performed in adults >= 65 y, receiving (1) no care, (2) home care/assisted living facility, or (3) care in a residential living facility. Sarcopenia was defined according to the European Working Group on Sarcopenia algorithm. Disability in ADL was measured with the Groningen Activity Restriction Scale (GARS); QoL with the EQ-5D-5L. Subjects were questioned about their health care use and health-related costs (societal perspective). Data are presented for sarcopenic and (age and sex matched) non-sarcopenic subjects. Bootstrapping was performed to estimate 95%CI around the mean costs. Several subgroup (age, sex, living situation, comorbidities) and sensitivity analyses were performed.Results: Sarcopenic subjects (n = 53) scored significantly worse on health-related outcomes compared with non-sarcopenic subjects (n = 174; GARS 29 +/- 11.3 vs. 22 +/- 7.3, P <0.001, QoL 0.78 +/- 0.2 vs. 0.86 +/- 0.2, P = 0.001). This difference was, except for the subscale ADL, no longer significant when compared with age and sex matched non-sarcopenic subjects (GARS 27 +/- 10.6, P = 0.097, QoL 0.81 +/- 0.2, P = 0.362). Mean health care costs of sarcopenic subjects ((sic)4325, 95% CI: (sic)3198-(sic)5471) were significantly higher than those of non-sarcopenics ((sic)1533, 95% CI: (sic)1153-(sic)1912), and higher, i.e. (sic)1557 per three months (though not significant) compared with age and sex matched non-sarcopenics ((sic)2768, 95% CI: (sic)1914-(sic)3743). Living situation (residential care) was a main driver of costs.Conclusions: Community-dwelling sarcopenic older adults had a higher health and economic burden than non-sarcopenic older adults. This was importantly driven by the living situation -keeping older adults independent and out of care-dependent settings may contribute to a reduction of health care costs. (C) 2016 Elsevier Masson SAS and European Union Geriatric Medicine Society. All rights reserved.",

keywords = "Muscle mass, Independently living, Assisted living, Costs, Disability, Quality of life, PHYSICAL-DISABILITY, MUSCLE MASS, HERTFORDSHIRE COHORT, INCIDENT DISABILITY, CARE COSTS, PEOPLE, LIFE, FRAILTY, PREDICTION, STRENGTH",

author = "D.M. Mijnarends and J.M.G.A. Schols and R.J.G. Halfens and J.M.M. Meijers and Y.C. Luiking and S. Verlaan and S.M.A.A. Evers",

year = "2016",

month = jun,

doi = "10.1016/j.eurger.2015.12.011",

language = "English",

volume = "7",

pages = "276--284",

journal = "European Geriatric Medicine",

issn = "1878-7649",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Burden-of-illness of Dutch community-dwelling older adults with sarcopenia: health related outcomes and costs

AU - Mijnarends, D.M.

AU - Schols, J.M.G.A.

AU - Halfens, R.J.G.

AU - Meijers, J.M.M.

AU - Luiking, Y.C.

AU - Verlaan, S.

AU - Evers, S.M.A.A.

PY - 2016/6

Y1 - 2016/6

N2 - Objective: To explore the burden-of-illness of Dutch community-dwelling older adults with sarcopenia, in terms of disability in activities of daily living (ADL), quality of life (QoL) and costs from a societal perspective.Methods: The Maastricht Sarcopenia Study (MaSS) was performed in adults >= 65 y, receiving (1) no care, (2) home care/assisted living facility, or (3) care in a residential living facility. Sarcopenia was defined according to the European Working Group on Sarcopenia algorithm. Disability in ADL was measured with the Groningen Activity Restriction Scale (GARS); QoL with the EQ-5D-5L. Subjects were questioned about their health care use and health-related costs (societal perspective). Data are presented for sarcopenic and (age and sex matched) non-sarcopenic subjects. Bootstrapping was performed to estimate 95%CI around the mean costs. Several subgroup (age, sex, living situation, comorbidities) and sensitivity analyses were performed.Results: Sarcopenic subjects (n = 53) scored significantly worse on health-related outcomes compared with non-sarcopenic subjects (n = 174; GARS 29 +/- 11.3 vs. 22 +/- 7.3, P <0.001, QoL 0.78 +/- 0.2 vs. 0.86 +/- 0.2, P = 0.001). This difference was, except for the subscale ADL, no longer significant when compared with age and sex matched non-sarcopenic subjects (GARS 27 +/- 10.6, P = 0.097, QoL 0.81 +/- 0.2, P = 0.362). Mean health care costs of sarcopenic subjects ((sic)4325, 95% CI: (sic)3198-(sic)5471) were significantly higher than those of non-sarcopenics ((sic)1533, 95% CI: (sic)1153-(sic)1912), and higher, i.e. (sic)1557 per three months (though not significant) compared with age and sex matched non-sarcopenics ((sic)2768, 95% CI: (sic)1914-(sic)3743). Living situation (residential care) was a main driver of costs.Conclusions: Community-dwelling sarcopenic older adults had a higher health and economic burden than non-sarcopenic older adults. This was importantly driven by the living situation -keeping older adults independent and out of care-dependent settings may contribute to a reduction of health care costs. (C) 2016 Elsevier Masson SAS and European Union Geriatric Medicine Society. All rights reserved.

AB - Objective: To explore the burden-of-illness of Dutch community-dwelling older adults with sarcopenia, in terms of disability in activities of daily living (ADL), quality of life (QoL) and costs from a societal perspective.Methods: The Maastricht Sarcopenia Study (MaSS) was performed in adults >= 65 y, receiving (1) no care, (2) home care/assisted living facility, or (3) care in a residential living facility. Sarcopenia was defined according to the European Working Group on Sarcopenia algorithm. Disability in ADL was measured with the Groningen Activity Restriction Scale (GARS); QoL with the EQ-5D-5L. Subjects were questioned about their health care use and health-related costs (societal perspective). Data are presented for sarcopenic and (age and sex matched) non-sarcopenic subjects. Bootstrapping was performed to estimate 95%CI around the mean costs. Several subgroup (age, sex, living situation, comorbidities) and sensitivity analyses were performed.Results: Sarcopenic subjects (n = 53) scored significantly worse on health-related outcomes compared with non-sarcopenic subjects (n = 174; GARS 29 +/- 11.3 vs. 22 +/- 7.3, P <0.001, QoL 0.78 +/- 0.2 vs. 0.86 +/- 0.2, P = 0.001). This difference was, except for the subscale ADL, no longer significant when compared with age and sex matched non-sarcopenic subjects (GARS 27 +/- 10.6, P = 0.097, QoL 0.81 +/- 0.2, P = 0.362). Mean health care costs of sarcopenic subjects ((sic)4325, 95% CI: (sic)3198-(sic)5471) were significantly higher than those of non-sarcopenics ((sic)1533, 95% CI: (sic)1153-(sic)1912), and higher, i.e. (sic)1557 per three months (though not significant) compared with age and sex matched non-sarcopenics ((sic)2768, 95% CI: (sic)1914-(sic)3743). Living situation (residential care) was a main driver of costs.Conclusions: Community-dwelling sarcopenic older adults had a higher health and economic burden than non-sarcopenic older adults. This was importantly driven by the living situation -keeping older adults independent and out of care-dependent settings may contribute to a reduction of health care costs. (C) 2016 Elsevier Masson SAS and European Union Geriatric Medicine Society. All rights reserved.

KW - Muscle mass

KW - Independently living

KW - Assisted living

KW - Costs

KW - Disability

KW - Quality of life

KW - PHYSICAL-DISABILITY

KW - MUSCLE MASS

KW - HERTFORDSHIRE COHORT

KW - INCIDENT DISABILITY

KW - CARE COSTS

KW - PEOPLE

KW - LIFE

KW - FRAILTY

KW - PREDICTION

KW - STRENGTH

U2 - 10.1016/j.eurger.2015.12.011

DO - 10.1016/j.eurger.2015.12.011

M3 - Article

SN - 1878-7649

VL - 7

SP - 276

EP - 284

JO - European Geriatric Medicine

JF - European Geriatric Medicine

IS - 3

ER -

Burden-of-illness of Dutch community-dwelling older adults with sarcopenia: health related outcomes and costs

Abstract

Keywords

Access to Document

Fingerprint

Cite this